2024-514333-37-00招募中2 期
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- iOnctura SA
- 入组人数
- 43
- 试验地点
- 10
- 主要终点
- OS is defined as the time from randomisation until death from any cause.
研究概览
简要总结
To evaluate clinical efficacy of roginolisib, as single agent, against Investigator´s choice of therapy by assessment of OS
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Male or female aged 18 years or older
- •Histologically or cytologically proven diagnosis of advanced or metastatic UM or ocular melanoma (arising from ocular melanocytes regardless of intraocular location);
- •Patients who have progressed following at least 1 prior immunotherapy treatment for advanced or metastatic UM. For patients who are HLA-A*02:01 positive prior treatment should have included tebentafusp, if available or patients clinically suitable. Patients who have also received prior melphalan hepatic infusion may be included;
- •Presence of at least one lesion suitable for biopsy. Biopsies will be mandatory at Screening and C5D1
- •Presence of at least one measurable lesion as per RECIST v1.
- •Any lesion that is biopsied cannot be used as a measurable lesion for the purposes of RECIST v1.1 assessments;
- •ECOG performance status of 0 to 1
- •Male or female patients of child-bearing potential must be willing to use highly effective forms of contraception (refer to APPENDIX 7 for details on highly effective methods of contraception and definitions of women of childbearing potential and of fertile men): a) Women of childbearing potential (WOCBP) must have a negative serum test as per local guidelines during screening and EOT and agree to have regular urine pregnancy testing throughout the study. WOCBP must agree to use highly effective method of contraception throughout the study and until 1 month after last dose of IMP; b) Male patients must agree to use barrier method of contraception [condom plus spermicide] from screening through Safety Follow-up visit, at least 1 month after the last dose of IMP. Men should refrain from donating sperm from the day of first dose of IMP, throughout the study and until 3 months after last dose of IMP. Men with partners of child-bearing potential must also be willing to ensure that their partner uses a highly effective method of contraception for the same duration. Men with pregnant or lactating partners should be advised to use barrier method contraception (e.g., condom plus spermicidal gel) to prevent exposure to the foetus or neonate;
- •All other relevant medical conditions must be well managed and stable, in the Investigator’s opinion, for at least 28 days prior to first dose of roginolisib;
- •Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
排除标准
- •Inability to swallow oral medication;
- •Malignant disease, other than that being treated in this study (e.g., skin/cutaneous and/or mucosal melanoma). Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to first dose of IMP; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type;
- •Any medical condition that would, in the Investigator's or Sponsor's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results;
- •Treatment with anti-tumour medications or investigational drugs within 14 days or 5 half-lives (whichever is longer) of administration of first dose of IMP;, with the exception of prior anticancer agents with long half-lives (e.g., PD-1/PD-L1 targeting agents), which are required to have a washout of 4 weeks prior to the first dose of IMP;
- •Major surgery within 2 weeks of the first dose of IMP (minimally invasive procedures such as bronchoscopy, tumour biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary
- •Radiotherapy within 4 weeks of the first dose of IMP, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumour mass;
- •Pregnant, likely to become pregnant, or lactating women
- •a). History of a prior Grade 3 or 4 irAE or any grade ocular irAE from prior immunotherapy which did not respond to corticosteroid therapy or resolved with treatment interruptions and returned to at least Grade 1; b). Have not recovered from toxic effect(s) of prior therapy to ≤ Grade 1, other than alopecia or fatigue or neuropathy which must be ≤ Grade 1;
- •Presence of symptomatic or untreated CNS metastases or CNS metastases that require doses of corticosteroids within the prior 3 weeks to first dose of roginolisib. Patients with brain metastases are eligible if lesions have been treated with localised therapy and there is no evidence of progressive disease for at least 4 weeks prior to the first dose of IMP;
- •Abnormal liver enzymes defined as: a) ALT or AST ≥ 3× upper limit of normal (ULN) (≥ 5× ULN in patients with liver metastases); b) Total bilirubin ≥ 1.5 × ULN are excluded unless direct bilirubin is ≤ ULN. If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin to be eligible (except patients with Gilbert syndrome);
- •Any other clinically significant out of range laboratory values;
- •Clinically significant cardiac disease or impaired cardiac function which may limit the patient´s participation in the clinical study. These may include unstable angina (i.e., not responsive to medical intervention), myocardial infarct in last 6 months, QTcF prolongation of more than 500 ms;
- •Evidence of interstitial lung disease or active, non-infectious pneumonitis, pulmonary fibrosis;
- •Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of IMP;
- •Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol;
结局指标
主要结局
OS is defined as the time from randomisation until death from any cause.
OS is defined as the time from randomisation until death from any cause.
次要结局
- • PFS is defined as the time from the date of the first dose of IMP until the earliest date of disease progression as determined by radiographic/objective disease assessment as per RECIST v1.1 provided by the Investigators, or death from any cause; • ORR is defined percentage of patients with a Complete Response (CR) or Partial Response (PR) determined by Investigator based on appropriate radiographic imaging and consistent with RECIST v1.1
- 1. (cont.)• DOR is defined as the time from the date of first documented response (CR, PR) by RECIST v1.1 until the date of documented progression or death in the absence of disease progression; • Time to Response is defined as the time from date of first dose of IMP until the date of first documented objective response, per RECIST v1.1 as assessed by Investigator;
- 1 (cont)• DCR defined as the proportion of patients with a Best Objective Response (BOR) of CR or PR or SD recorded at ≥8 weeks (±1 week), prior to any progressive disease event; • CBR is defined as the proportion of patients with a BOR of CR or PR or SD recorded at C5D1; • Survival probability defined as the probability that an individual survives from date of first dose of IMP until 6 months, 9 months, 12 months and 24 months after end of treatment. Median survival time will also be estimated.
- 2. Safety and tolerability will be assessed by: • Evaluation of AEs during treatment and followup using National Cancer Institute (NCI) CTCAE v5.0; • Laboratory parameters; • Vital signs, physical examination, 12-lead electrocardiogram (ECG), Eastern Cooperative Oncology Group (ECOG) performance status;
- 3. Concentration of roginolisib at pre-dose and steady state levels (including AUC, population PK);
- 4. Changes in PRO relative to baseline using following questionnaires: • EQ-5D-5L; • European Organisation for Research Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30; • Epworth Sleepiness Scale (ESS); • Fatigue Severity Scale (FSS).
- 5. Safety and tolerability will be assessed by: • Evaluation of AEs during treatment and followup using NCI CTCAE v5.0; • Laboratory parameters; • Vital signs, physical examination, 12-lead ECG, ECOG performance status.
- 6. Assessed by health resource use (e.g., hospitalisations, outpatient visits, emergency visits, preparation and time for IMP administration, etc)
研究者
Michael Lhan
Scientific
iOnctura SA
研究点 (10)
Loading locations...
相似试验
招募中
3 期
5% KOH solution vs placebo treatment of actinic keratosis with different treatment durationActinic keratosis2024-514277-21-00INFECTOPHARM Arzneimittel und Consilium GmbH630
招募中
1 期
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT2024-519010-31-00Fondazione Melanoma Onlus80
已完成
1 期
A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers2024-515124-36-00Integrative Research Laboratories Sweden AB12
招募中
3 期
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliaNCT07285460Sanofi85
尚未招募
1 期
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid TumorsNCT07272590Qilu Pharmaceutical Co., Ltd.290